Shatpushpa arka in the management of Neonatal Jaundice (Najaat Kamala)

A single arm clinical study to evaluate the efficacy of Shatpushpa arka in Navajaata Kamala (Neonatal Jaundice)

Status

Recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/03/050552

Enrollment

Registered

2023-03-10

Start date

Unknown

Completion date

Unknown

Last updated

2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D50-D89- Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1 Patient having bilirubin 6 mg/dl To 14 mg/dl 2 The patients presenting the signs and symptoms of Kamala such as pittavarni Netra Mukh Nakh Vinmutra Icterus over body 3 The patients whose parents are ready to participate in the clinical trial by giving informed written consent

Exclusion criteria

Exclusion criteria: 1 Newborn having life threatening illness 2 Newborns who are known cases of chronic systemic illness Like Septicemia

Design outcomes

Primary

Measure	Time frame
To evaluate the efficacy of shatapushpa arka in decreasing level of Sr.bilirubin in NewbornTimepoint: Follow up will be taken on 3rd Day and 7th day Drug will be given for total 7days	—

Secondary

Measure	Time frame
Shatpushpa Arka will be given to patient for total 7daysTimepoint: follow up on -3rd and 7th day. Total duration of study will be 7 days	—

Countries

India

Contacts

Public ContactDR Sachin R Bhagawat

DR D Y Patil college of ayurveda and research centre pimpri pune

sbhagwat777@gmail.com9511223623

Outcome results